Under the terms of the agreement, Standard Chemical & Pharmaceutical has the exclusive development and manufacturing rights and Cypress Pharmaceutical has exclusive US marketing rights of the generic drug products.
Max Draughn, Cypress Pharmaceutical’s CEO, said: “We are very pleased Standard has chosen to partner with us and utilize Cypress’s strong US marketing position. As a seasoned global pharmaceutical company with significant experience in development and manufacturing, Standard is a complementary and compelling partner with Cypress.”